<DOC>
	<DOCNO>NCT00650572</DOCNO>
	<brief_summary>This Phase 1 study patient advance HER2+ solid malignancy HER2+ metastatic breast cancer receive investigational study drug ARRY-380 . This study 2 part . In first part , patient advance HER2+ solid malignancy , already receive least one previous standard therapy , receive increase dos study drug order achieve high dose study drug possible cause unacceptable side effect . Approximately 30 patient US enrol Part 1 ( Completed ) . In second part study , patient HER2+ metastatic breast cancer , already receive least one previous standard therapy , receive best dose study drug determine first part study follow see side effect effectiveness study drug , , treat cancer . Approximately 20 patient US enrol Part 2 ( Active , recruit ) .</brief_summary>
	<brief_title>A Study ARRY-380 Patients With Advanced HER2+ Cancer</brief_title>
	<detailed_description />
	<criteria>Key Inclusion Criteria ( Part 1 Part 2 ) : Histological cytological evidence HER2+ cancer ( Part 1 ) HER2+ metastatic breast cancer ( Part 2 ) . Patients receive least one previous therapeutic regimen either longer candidate standard therapy , standard therapy available , choose pursue standard therapy ( patient HER2+ breast cancer clinical indication trastuzumab lapatinib receive prior therapy trastuzumab lapatinib , available ) . Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 0 2 . Additional criterion exist . Key Exclusion Criteria ( Part 1 Part 2 ) : Uncontrolled symptomatic brain metastasis ( patient may consider adequately control stable steroid dose least 30 day ) . Treatment investigational medicinal product device within 30 day prior first dose study drug . Radiotherapy within 28 day prior first dose study drug ( include palliative radiotherapy focal site ) . Chemotherapy within 21 day prior first dose study drug . Major surgery within 30 day prior first dose study drug . Known positive serology human immunodeficiency virus ( HIV ) , hepatitis B and/or active hepatitis C. Additional criterion exist .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>human epidermal growth factor receptor 2</keyword>
	<keyword>epidermal growth factor receptor</keyword>
	<keyword>EGFR</keyword>
	<keyword>type I receptor tyrosine kinase</keyword>
</DOC>